

2015

英文論文

1. 2015 Adachi T, Sakurai T, Kashida H, Mine H, Hagiwara S, Matsui S, Yoshida K, Nishida N, Watanabe T, Itoh K, Fujita J, **Kudo M**: Involvement of heat shock protein A4/Apg-2 in refractory inflammatory bowel disease. **Inflamm Bowel Dis** 21:31-39, 2015 (IF=4.464).
2. 2015 **Kudo M**: Malignant transformation of hepatocellular adenoma: How frequently does it happen? **Liver Cancer** 1:1-5, 2015 (IF=0.000).
3. 2015 Togashi Y, Kogita A, Sakamoto H, Hayashi H, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Kitano M, Okuno K, **Kudo M**, Nishio K: Activin signal promotes cancer progression and is involved in cachexia in a subset of pancreatic cancer. **Cancer Lett** 356:819-827, 2015 (IF=5.621).
4. 2015 Cainap C, Qin S, Huang WT, Chung IJ, Pan H, Cheng Y, **Kudo M**, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens FA, Qian J, McKee MD, Ricker JL, Carlson DM, Nowiem SE: Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. **J Clin Oncol** 33:172-179, 2015 (IF=18.428).
5. 2015 Okumura N, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Kawasaki M, Tomita T, Umehara Y, Taniike S, Kono M, **Kudo M**: Percutaneous endoscopic gastrostomy with Funada-style gastropexy greatly reduces the risk of peristomal infection. **Gastroenterol Rep** 3:69-74, 2015(IF=0.000).
6. 2015 Nishida N, **Kudo M**: A bridge between multi-omics data and the

management of hepatocellular carcinoma. **Ann Transl Med** 3:1, 2015 (IF=0.000).

7. 2015 **Kudo M**: Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. **Liver Cancer** 4:39-50, 2015(IF=0.000).
8. 2015 **Kudo M**: Clinical practice guidelines for hepatocellular carcinoma differ between Japan, United States, and Europe. **Liver Cancer** 4:85-95, 2015 (IF=0.000).
9. 2015 Kitano M, Kamata K, Imai H, Miyata T, Yasukawa S, Yanagisawa A, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasonography for pancreatobiliary diseases. **Digest Endosc** 27:60-67, 2015 (IF=2.058).
10. 2015 Shiina T, Nightingale K, Palmeri M, Hall T, Bamber J, Barr R, Castera L, Choi B, Chou Y, Cosgrove D, Dietrich C, Ding H, Amy D, Farrokh A, Ferraioli G, Filice C, Friedrich-Rust M, Nakashima K, Schafer F, Sporea I, Suzuki S, Wilson S, **Kudo M**: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 1; basic principles and terminology. **Ultrasound Med Biol** 41:1126-1147, 2015 (IF=2.214).
11. 2015 **Kudo M**: Foreword to the WFUMB guideline and recommendations on the clinical use of ultrasound elastography. **Ultrasound Med Biol** 41:1125, 2015 (IF=2.214).
12. 2015 Ferraioli G, Filice C, Castera L, Choi B, Sporea I, Wilson S, Cosgrove D, Dietrich C, Amy D, Bamber J, Barr R, Chou Y, Ding H, Farrokh A, Friedrich-Rust M, Hall T, Nakashima K, Nightingale K, Palmeri M, Schafer F, Shiina T, Suzuki S, **Kudo M**: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part3; Liver. **Ultrasound Med Biol** 41:1161-1179, 2015 (IF=2.214).
13. 2015 Barr R, Nakashima K, Amy D, Cosgrove D, Farrokh A, Schafer F,

Bamber J, Castera L, Choi B, Chou Y, Dietrich C, Ding H, Ferraioli G, Filice C, Friedrich-Rust M, Hall T, Nightingale K, Palmeri M, Shiina T, Suzuki S, Sporea I, Wilson S, **Kudo M**: WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 2; Breast. **Ultrasound Med Biol** 41:1148-1160, 2015 (IF=2.214).

14. 2015 Okita K, Izumi N, Ikeda K, Osaki Y, Numata K, Ikeda M, Kokudo N, Imanaka K, Nishiguchi S, Kondo S, Nishigaki Y, Shiomi S, Ueshima K, Isoda N, Karino Y, **Kudo M**, Tanaka K, Kaneko S, Moriwaki H, Makuuchi M, Okusaka T, Hayashi N, Ohashi Y, Kumada H, and Peretinoin Study Group: Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized placebo-controlled trial. **J Gastroenterol** 50:667-674, 2015 (IF=4.523).
15. 2015 Okita K, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, **Kudo M**, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H, Peretinoin Study Group: Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study. **J Gastroenterol** 50:191-202, 2015 (IF=4.523).
16. 2015 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, **Kudo M**, REACH Trail Investigators: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. **Lancet Oncol** 16:859-870, 2015 (IF=24.690).
17. 2015 Sakurai T, Yada N, Watanabe T, Arizumi T, Hagiwara S, Ueshima

- K, Nishida N, Fujita J, **Kudo M**: Cold-inducible RNA-binding protein promotes the development of liver cancer. **Cancer Sci** 106:352-358, 2015 (IF=3.523).
18. 2015 Arai Y, Yamashita K, Kuriyama K, Shiokawa M, Kodama Y, Sakurai T, Mizugishi K, Uchida K, Kadowaki N, Takaori-Kondo A, **Kudo M**, Okazaki K, Strober W, Chiba T, Watanabe T: Plasmacytoid dendritic cell activation and IFN- α production are prominent features of murine autoimmune pancreatitis and human IgG4-related autoimmune pancreatitis. **J Immunol** 195:3033-3044, 2015 (IF=4.922).
19. 2015 Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, **Kudo M**: Primary leiomyosarcoma of the colon. **Clin J Gastroenterol** 8:217-222, 2015(IF=0.000).
20. 2015 Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, **Kudo M** and the investigators's study group: Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: a phase 2 randomized study. **J Hepatol** 63:896-904, 2015 (IF=11.336).
21. 2015 **Kudo M**: Value of dynamic contrast enhanced MRI in predicting outcomes of HCC receiving radiotherapy. **Hepatol Int** 9:155-156, 2015 (IF=1.780).
22. 2015 Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, **Kudo M**, Johnson P, Wagner S, Orsini LS, Sherman M: Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study. **Liver Int** 35:2155-2166, 2015 (IF=4.850).
23. 2015 Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, Blanc JF, Johnson P, **Kudo**

- M**, Roberts L, Sherman M: The role of hepatic resection in the treatment of hepatocellular cancer. **Hepatology** 62:440-451, 2015 (IF=11.055).
24. 2015 Sakurai T, Kashida H, Hagiwara S, Nishida N, Watanabe T, Fujita J, **Kudo M**: Heat shock protein A4 controls cell migration and gastric ulcer healing. **Digest Dis Sci** 60:850-857, 2015 (IF=2.613).
25. 2015 Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, Uemoto S, Kaneko S, Kawasaki S, Ku Y, **Kudo M**, Kubo S, Takayama T, Tateishi R, Fukuda T, Matsui O, Matsuyama Y, Murakami T, Arii S, Okazaki M, Makuuchi M: Evidence-based clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). **Hepatol Res** 45:123-127, 2015 (IF=2.735).
26. 2015 Pinato DJ, Arizumi T, Allara E, Jang JW, Smirne C, Kim YW, **Kudo M**, Pirisi M, Sharma R: Validation of the hepatoma arterial embolisation prognostic score in European and Asian populations and proposed modification. **Clin Gastroenterol Hepatol** 13:1204-1208, 2015 (IF=7.896).
27. 2015 **Kudo M**: Chronic Liver Diseases and Liver Cancer: An Update in 2015. **Digest Dis** 33:705-707, 2015 (IF=2.181).
28. 2015 Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, **Kudo M**: Early viral response predicts the efficacy of antiviral triple therapy with simeprevir, peg-interferon, and ribavirin in patients infected with hepatitis C virus genotype 1. **Digest Dis** 33:708-714, 2015 (IF=2.181).
29. 2015 Hasegawa Y, Kim SR, Hatae T, Ohta M, Fujinami A, Sugimoto K, Kim KI, Imoto S, Tohyama M, Kim SK, Ikura Y, **Kudo M**: Usefulness of cytokeratin-18M65 in diagnosing non-alcoholic

steatohepatitis in Japanese population. **Digest Dis** 33:715-720, 2015 (IF=2.181).

30. 2015 Sugimoto K, Kim SR, Imoto S, Tohyama M, Kim SK, Matsuoka T, Yano Y, **Kudo M**, Hayashi Y: Characteristics of hypovascular versus hypervascular well-differentiated hepatocellular carcinoma smaller than 2cm - focus on tumor size, markers and imaging detectability. **Digest Dis** 33:721-727, 2015 (IF=2.181).
31. 2015 Arizumi T, Ueshima K, Iwanishi M, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, **Kudo M**: Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience second analysis. **Digest Dis** 33:728-734, 2015 (IF=2.181).
32. 2015 Nishida N, Iwanishi M, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, Kitano M, **Kudo M**: Hepatic DNA methylation is affected by hepatocellular carcinoma risk in patients with and without hepatitis virus. **Digest Dis** 33:745-750, 2015 (IF=2.181).
33. 2015 **Kudo M**, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N: Subclassification of BCLC stage hepatocellular carcinoma and treatment strategies: Proposal of modified Bolondi subclassification (Kinki Criteria). **Digest Dis** 33:751-758, 2015 (IF=2.181).
34. 2015 Minami Y, Murakami T, Kitano M, Sakurai T, Nishida N, **Kudo M**: Cone-beam CT angiography for hepatocellular carcinoma: current status. **Digest Dis** 33:759-764, 2015 (IF=2.181).
35. 2015 **Kudo M**, Kitano M, Sakurai T, Nishida N: General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the Liver Cancer Study Group of Japan. **Digest**

Dis 33:765-770, 2015 (IF=2.181).

36. 2015 Nishida N, Kitano M, Sakurai T, **Kudo M**: Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma. **Digest Dis** 33:771-779, 2015 (IF=2.181).
37. 2015 **Kudo M**, Kitano M, Sakurai T, Nishida N: Challenges of clinical research on hepatocellular carcinoma. **Digest Dis** 33:780-790, 2015 (IF=2.181).
38. 2015 **Kudo M**: Evidence and consensus on management of hepatocellular carcinoma: update in 2015. **Oncology** 89:1-3, 2015 (IF=2.422).
39. 2015 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Nishida N, Kitano M, **Kudo M**: Evaluation of ART scores for repeated transarterial chemoembolization in Japanese patients with hepatocellular carcinoma. **Oncology** 89:4-10, 2015(IF=2.422).
40. 2015 Ogawa C, Minami Y, Noda T, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki H, Shibatoge M, **Kudo M**: Initial experience performing percutaneous ultrasound examination with real-time virtual sonography with color display. **Oncology** 89:11-18, 2015(IF=2.422).
41. 2015 Kariyama K, Wakuta A, Nishimura M, Kishida M, Oonishi A, Ohyama A, Nouso K, **Kudo M**: Percutaneous radiofrequency ablation for Intermediate-stage hepatocellular carcinoma. **Oncology** 89:19-26, 2015(IF=2.422).
42. 2015 Minami Y, Minami T, Chishina H, Arizumi T, Takita M, Kitai S, Yada N, Hagiwara S, Tsurusaki M, Yagyu Y, Ueshima K, Nishida N, Murakami T, **Kudo M**: Balloon-occluded transcatheter arterial

chemoembolization for hepatocellular carcinoma: a single-center experience. **Oncology** 89:27-32, 2015(IF=2.422).

43. 2015 Tochio H, Sugahara M, Imai Y, Tei H, Suginoshita Y, Iwasaki N, Sasaki I, Hamada M, Minowa K, Inokuma T, **Kudo M**: Hyperenhanced rim surrounding liver metastatic tumors in the postvascular phase of sonazoid-enhanced ultrasonography: a histological indication of the presence of Kupffer cells. **Oncology** 89:33-41, 2015 (IF=2.422).
44. 2015 Sugimoto K, Kim SR, Kim SK, Imoto S, Tohyama M, Kim KI, Ohtani A, Hatae T, Yano Y, **Kudo M**, Hayashi Y: Comparison of daclatasvir and asunaprevir for chronic HCV 1b infection with telaprevir and simeprevir plus peginterferon and ribavirin, with a focus on the prevention of occurrence and recurrence of hepatocellular carcinoma. **Oncology** 89:42-46, 2015 (IF=2.422).
45. 2015 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Ida H, Minami Y, Sakurai T, Kitano M, Nishida N, **Kudo M**: Validation of a modified substaging system (Kinki Criteria) for patients with intermediate-stage hepatocellular carcinoma. **Oncology** 89:47-52, 2015(IF=2.422).
46. 2015 Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ueshima K, Ida H, Nishida N, **Kudo M**: A newly developed shear wave elastography modality: with a unique reliability index. **Oncology** 89:53-59, 2015(IF=2.422).
47. 2015 Kim SK, Kim SR, Imoto S, Tohyama M, Otono Y, Tamura T, Kim KI, Kobayashi M, Ohtani A, Sugimoto K, Mizuguchi A, Hiramatsu Y, **Kudo M**: Recent advances in the management of chronic hepatitis B including suppression of hepatocellular carcinoma by entecavir and interferon. **Oncology** 89:60-69, 2015 (IF=2.422).
48. 2015 Hagiwara S, Nishida N, **Kudo M**: Antiviral therapy for chronic

hepatitis B: combination of nucleoside analogs and interferon. **World J Hepatol** 7:2427-2431, 2015 (IF=0.000).

49. 2015 Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, **Kudo M**, Cai J, Poon RT, Han KH, Tak WY, Lee HC, Song T, Roayaie S, Bolondi L, Lee KS, Makuuchi M, Souza F, Le Berre MA, Meinhardt G, Llovet JM: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. **Lancet Oncol** 16:1344-1354, 2015 (IF=24.690).
50. 2015 Ueshima K, **Kudo M**, Tanaka M, Kumada T, Chung H, Hagiwara S, Inoue T, Yada N, Kitai S: Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. **Liver Cancer** 4:263-273, 2015 (IF=0.000).
51. 2015 **Kudo M**: Molecular targeted therapy for hepatocellular carcinoma: where are we now? **Liver Cancer** 4:1-7, 2015 (IF=0.000).
52. 2015 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, **Kudo M**: Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. **Liver Cancer** 4:253-262, 2015 (IF=0.000).
53. 2015 **Kudo M**: Immune checkpoint blockade in hepatocellular carcinoma. **Liver Cancer** 4:201-207, 2015 (IF=0.000).
54. 2015 Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin SK, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, **Kudo M**: Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. **Ann Oncol**

26:2457-2463, 2015 (IF=7.040).

55. 2015 Yamao K, Kitano M, **Kudo M**, Maenishi O: Synchronous pancreatic and gastric metastasis from an ovarian adenocarcinoma diagnosed by endoscopic ultrasound-guided fine-needle aspiration. **Endoscopy** 47:E596-597, 2015 (IF=5.053).
56. 2015 Hagiwara S, Nishida N, Park AM, Sakurai T, Kawada A, **Kudo M**: Impaired expression of ATP-binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. **Hepatology** 62:1638-1689, 2015 (IF=11.055).
57. 2015 Okada M, Murakami T, Yada N, Numata K, Onoda M, Hyodo T, Inoue T, Ishii K, **Kudo M**: Comparison between T1 relaxation time of Gd-EOB-DTPA enhanced MRI and liver stiffness measurement of Ultrasound elastography in the evaluation of cirrhotic liver. **J Magn Reson Imaging** 41:329-338, 2015 (IF=3.210).
58. 2015 Utsunomiya T, Shimada M, **Kudo M**, Ichida T, Matsui O, Izumi N, Matsuyama Y, Sakamoto M, Nakashima O, Ku Y, Takayama T, Kokudo N, for the Liver Cancer Study Group of Japan: A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: A nationwide study of 11, 950 patients. **Ann Surg** 261:513-520, 2015 (IF=8.327).
59. 2015 Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, **Kudo M**, Takayama T, Nakashima O, Liver Cancer Study Group of Japan: Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. **Cancer** 122:61-70, 2015 (IF=5.068).
60. 2015 Minami Y, **Kudo M**: Imaging modalities for assessment of

treatment response to nonsurgical hepatocellular carcinoma therapy: Contrast-enhanced US, CT and MRI. **Liver Cancer** 4:106-114, 2015 (IF=0.000).

61. 2015 Matsui S, **Kudo M**, Kitano M, Asakuma Y: Evaluation of the response to chemotherapy in advanced gastric cancer by contrast-enhanced harmonic EUS. **Hepato-Gastroenterol** 62:595-598, 2015 (IF=0.928).
62. 2015 Takahashi H, Ikeda M, Kumada T, Osaki Y, Kondo S, Kusumoto S, Ohkawa K, Nadano S, Furuse J, **Kudo M**, Ito K, Yokoyama M, Okusaka T, Shimoyama M, Mizokami M: Multicenter cooperative case survey of hepatitis B Virus reactivation by chemotherapeutic agents. **Hepatol Res** 45:1220-1227, 2015 (IF=2.735).
63. 2015 **Kudo M**: Locoregional therapy for hepatocellular carcinoma. **Liver Cancer** 4:163-164, 2015 (IF=0.000).
64. 2015 Yutani S, Ueshima K, Abe K, Ishiguro A, Eguchi J, Matsueda S, Komatsu N, Shichijo S, Yamada A, Itoh K, Sasada T, **Kudo M**, Noguchi M: Phase II study of personalized peptide vaccination with both a hepatitis C virus-derived peptide and peptides from tumor-associated antigens for the treatment of HCV-positive advanced hepatocellular carcinoma patients. **J Immunol Res** 2015; 2015: 473909. doi: 10.1155/2015/473909. Epub 2015 Oct 11. (IF=0.000).